Dermatology

 
Atopic Dermatitis Flare Frequency May Predict Future Disease Severity, According to New Findings
July 21, 2025

Atopic dermatitis flares should be factored in to an assessment of disease severity and prognosis, the authors note, and a threshold established for acceptable frequency.

Lebrikizumab Maintains Skin Clearance Through 3 Years in AD Patients: Daily Dose
July 21, 2025

Your daily dose of the clinical news you may have missed.

Dupilumab Sustains Long-Term Reduction of S. aureus in People with AD: Daily Dose
July 16, 2025

Your daily dose of the clinical news you may have missed.

Lebrikizumab Found Safe, Effective in Patients With Skin of Color With AD: Daily Dose
July 15, 2025

Your daily dose of the clinical news you may have missed.

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment
July 08, 2025

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

Apogee Hopes Raised by Phase 2 Data for APG777 to be a Best-In-Class for Atopic Dermatitis
July 07, 2025

The investigational IL-13 inhibitor showed topline EASI-75 of 66.9% and reduced injection frequency in part A of the APEX phase 2 clinical trial.

Mental Health Burden in Atopic Dermatitis: Study Identifies Key Risk Factors for Anxiety and Depression
July 02, 2025

Depression and anxiety affect as many as 1 in 4 people with AD, with pruritus, sleep disorders, education level, and comorbidities identified as independent risk factors.

Roflumilast Cream 0.15% Receives Strong Recommendation for Atopic Dermatitis in AAD Guideline Update
June 26, 2025

Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.

Why Is Early Treatment of Atopic Dermatitis So Important? Mona Shahriari, MD, Says It Could Change a Life
June 26, 2025

Atopic dermatitis is not just "another rash on the schedule. It could be the reason that patient doesn't leave the house," Shahriari says.

Investigational Rezpegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe Atopic Dermatitis
June 25, 2025

In the phase 2b trial, the IL-2 pathway agonist and Treg proliferator demonstrated a strong dose-dependent biological response across 3 treatment arms vs placebo.